The Eliminator: A design of a close air support aircraft

The Eliminator is the answer to the need for an affordable, maintainable, survivable, high performance close air support aircraft primarily for the United States, but with possible export sales to foreign customers. The Eliminator is twin turbofan, fixed wing aircraft with high mounted canards and low mounted wings. It is designed for high subsonic cruise and an attack radius of 250 nautical miles. Primarily it would carry 20 500 pound bombs as its main ordnance , but is versatile enough to carry a variety of weapons configurations to perform several different types of missions. It carries state of the art navigation and targeting systems to deliver its payload with pinpoint precision and is designed for maximum survivability of the crew and aircraft for a safe return and quick turnaround. It can operate from fields as short as 1800 ft. with easy maintenance for dispersed operation during hostile situations. It is designed for exceptional maneuverability and could be used in a variety of roles from air-to-air operations to anti-submarine warfare and maritime patrol duties

Real-time atomic absorption mercury continuous emission monitor

A continuous emission monitor (CEM) for mercury(Hg) in combustor flue gas streams has been designed and tested for the detection of Hg by optical absorption. A sampling system that allows continuous introduction of stack gas is incorporated into the CEM, for the sequential analysis of elemental and total Hg. A heated pyrolysis tube is used in the system to convert oxidizedHg compounds to elemental Hg for analysis of total Hg; the pyrolysis tube is bypassed to determine the elemental Hg concentration in the gas stream. A key component of the CEM is a laboratory-designed and -assembled echelle spectrometer that provides simultaneous detection of all of the emission lines from a Hg pen lamp, which is used as the light source for the optical absorption measurement. This feature allows for on-line spectroscopic correction for interferent gases such as sulfur dioxide and nitrogen dioxide, typically present in combustion stack gas streams, that also absorb at the Hg detection wavelength (253.65 nm). This article provides a detailed description of the CEM system, the characteristics and performance of the CEM, and the results of field tests performed at the Environmental Protection Agency-Rotary Kiln at Research Triangle Park, NC

Real-time atomic absorption mercury continuous emission monitor

A continuous emission monitor (CEM) for mercury(Hg) in combustor flue gas streams has been designed and tested for the detection of Hg by optical absorption. A sampling system that allows continuous introduction of stack gas is incorporated into the CEM, for the sequential analysis of elemental and total Hg. A heated pyrolysis tube is used in the system to convert oxidizedHg compounds to elemental Hg for analysis of total Hg; the pyrolysis tube is bypassed to determine the elemental Hg concentration in the gas stream. A key component of the CEM is a laboratory-designed and -assembled echelle spectrometer that provides simultaneous detection of all of the emission lines from a Hg pen lamp, which is used as the light source for the optical absorption measurement. This feature allows for on-line spectroscopic correction for interferent gases such as sulfur dioxide and nitrogen dioxide, typically present in combustion stack gas streams, that also absorb at the Hg detection wavelength (253.65 nm). This article provides a detailed description of the CEM system, the characteristics and performance of the CEM, and the results of field tests performed at the Environmental Protection Agency-Rotary Kiln at Research Triangle Park, NC.The following article appeared in Review of Scientific Instruments 74, 8 (2003); 3774 and may be found at doi: 10.1063/1.1589158.</p

Vorapaxar in the secondary prevention of atherothrombotic events

Item does not contain fulltextBACKGROUND: Thrombin potently activates platelets through the protease-activated receptor PAR-1. Vorapaxar is a novel antiplatelet agent that selectively inhibits the cellular actions of thrombin through antagonism of PAR-1. METHODS: We randomly assigned 26,449 patients who had a history of myocardial infarction, ischemic stroke, or peripheral arterial disease to receive vorapaxar (2.5 mg daily) or matching placebo and followed them for a median of 30 months. The primary efficacy end point was the composite of death from cardiovascular causes, myocardial infarction, or stroke. After 2 years, the data and safety monitoring board recommended discontinuation of the study treatment in patients with a history of stroke owing to the risk of intracranial hemorrhage. RESULTS: At 3 years, the primary end point had occurred in 1028 patients (9.3%) in the vorapaxar group and in 1176 patients (10.5%) in the placebo group (hazard ratio for the vorapaxar group, 0.87; 95% confidence interval [CI], 0.80 to 0.94; P<0.001). Cardiovascular death, myocardial infarction, stroke, or recurrent ischemia leading to revascularization occurred in 1259 patients (11.2%) in the vorapaxar group and 1417 patients (12.4%) in the placebo group (hazard ratio, 0.88; 95% CI, 0.82 to 0.95; P=0.001). Moderate or severe bleeding occurred in 4.2% of patients who received vorapaxar and 2.5% of those who received placebo (hazard ratio, 1.66; 95% CI, 1.43 to 1.93; P<0.001). There was an increase in the rate of intracranial hemorrhage in the vorapaxar group (1.0%, vs. 0.5% in the placebo group; P<0.001). CONCLUSIONS: Inhibition of PAR-1 with vorapaxar reduced the risk of cardiovascular death or ischemic events in patients with stable atherosclerosis who were receiving standard therapy. However, it increased the risk of moderate or severe bleeding, including intracranial hemorrhage. (Funded by Merck; TRA 2P-TIMI 50 ClinicalTrials.gov number, NCT00526474.)